This should improve its effectiveness both as a probiotic and as a treatment for diarrhea. Acknowledgments Our laboratory is supported by the following grants awarded to N. Austriaco: NIGMS R15 GM094712, NSF MRI-R2 0959354, NIH Grant 8 P20 GM103430-12 to the Rhode Island INBRE Program for student training, and a CAFR faculty research grant from Providence College. The funders had no role in study design, data collection AZD1080 mw and analysis, decision to publish, or preparation of the manuscript. Non nisi te, Domine. Electronic supplementary material Additional file 1: Differentially Regulated Genes

in S. boulardii Cells Cultured in an Acidic Environment. S. boulardii genes showing 4-fold or greater increase (up-regulated) or decrease (down-regulated) expression in response to an acidic environment. This data has been submitted to the Gene Expression Omnibus (GEO) at the NCBI with accession number, GSE43271. (XLS 286 kb) (XLS 286 KB) References 1. FAO/WHO: Guidelines for the Evaluation of Probitics in Food. Food and Agriculture Organization

of the United Nations: In. London Ontario, Canada: World Health Organization; 2002. 2. Gismondo MR, Drago L, Lombardi A: Review of probiotics available to modify gastrointestinal flora. Int J Antimicrob Agents 1999,12(4):287–292.PubMedCrossRef 3. McCullough MJ, Clemons KV, McCusker JH, Stevens DA: Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998,36(9):2613–2617.Emricasan supplier PubMed 4. Htwe K, Yee KS, Tin M, Vandenplas Y: Effect of Saccharomyces boulardii 3-oxoacyl-(acyl-carrier-protein) reductase in the treatment this website of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg 2008,78(2):214–216.PubMed 5. McFarland LV: Meta-analysis of probiotics for the prevention

of traveler’s diarrhea. Travel Med Infect Dis 2007,5(2):97–105.PubMedCrossRef 6. Brassart DSE: The use of probiotics to reinforce mucosal defense mechanisms. Trends Food Sci Technol 1997, 8:321–326.CrossRef 7. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D: The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000,31(4):1012–1017.PubMedCrossRef 8. Tung JM, Dolovich LR, Lee CH: Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Can J Gastroenterol 2009,23(12):817–821.PubMed 9. Dinleyici EC, Eren M, Ozen M, Yargic ZA, Vandenplas Y: Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther 2012,12(4):395–410.PubMedCrossRef 10. Sudha MR, Bhonagiri S, Kumar MA: Oral consumption of potential probiotic Saccharomyces boulardii strain Unique 28 in patients with acute diarrhoea: a clinical report. Benef Microbes 2012,3(2):145–150.PubMedCrossRef 11.